MedTrace Logo

LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

NCT05327361 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2024-04-03

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to measure the depigmenting effect of a serum product called Liftactiv B3 in patients with mild to moderate facial PIHP (Post Inflammatory Hyper Pigmentation)

Conditions

  • Acne
  • Post Inflammatory Hyperpigmentation

Interventions

DRUG

Liftactiv B3

Participants will apply a dime size amount of the serum to 1 side of the face.

OTHER

Sunscreen

Participants will apply a dime size amount of sunscreen to cover the other half of the face.

Sponsors & Collaborators

  • Vichy Laboratoires

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-22
Primary Completion
2023-01-17
Completion
2023-03-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05327361 on ClinicalTrials.gov